Clifford Rosen, MD, chair of the Endocrine Society's 2019 clinical practice guideline for the pharmacological management of osteoporosis in postmenopausal women, reviews key points of the new guideline.
Clifford Rosen, MD, is an endocrinologist, bone biologist, director of Clinical and Translational Research and senior scientist at Maine Medical Center’s Research Institute, and professor of medicine at Tufts University School of Medicine. He is also a member of the US Food and Drug Administration's Advisory Panel on Endocrinologic and Metabolic Drugs and associate editor of the New England Journal of Medicine.
*Note: A formal amendment to the 2019 guideline was recently issued regarding romosozumab. Click here to read about the update.
Additional Resources:
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. https://doi.org/10.1210/jc.2019-00221
